A Phase 3 interventional study of Bemnifosbuvir (BEM) and Placebo in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection) and COVID-19, sponsored by Atea Pharmaceuticals, Inc.. Completed at 264 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-13.
Sponsored by Atea Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.
Among the 1,859 studies in COVID-19 with a site in United States, this one is the 103rd largest by enrollment of the 1,321 interventional ones that give a count, is one of 223 that started in 2022, is one of 174 in phase 3, and was the 1,570th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
Shionogi · Sites in United States, Bulgaria, Japan
Ages 12+
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,859 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 240 · Phase 2 481 · Phase 3 244 · Phase 4 60
First in 2007; this study’s year is marked. 223 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,285 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 91 across the 1,321 interventional studies, 300 across the 521 observational. Of the 1,414 that completed or were terminated, 720 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
638 of 1,859 have an industry lead sponsor. The 10 most frequent:
Atea Pharmaceuticals, Inc. is the lead sponsor of 33 studies on the registry; 1 is open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 4 (16%) have results posted.
Atea Pharmaceuticals, Inc. has 2 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
85 of the studies in COVID-19 with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 85 to your calendar (.ics) → With an account.
Among the 1,859 studies in COVID-19 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate whether bemnifosbuvir (BEM) is effective and safe in adults with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease. Eligible subjects will be randomly assigned (by chance) to receive BEM or matching placebo orally for 5 days. Co-administration of locally available standard of care (SOC) is allowed. The total duration of the study is 60 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject must be high risk, defined below:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Bemnifosbuvir (BEM)
Drug: Placebo
BEM tablets administered orally every 12 hours (twice a day) for a total of 5 days
Also known as: AT-527
Placebo tablets administered orally every 12 hours (twice a day) for a total of 5 days
Percentage of Subjects Hospitalized for Any Cause or Died Due to Any Cause
Time frame: Day 1 through Day 29
Percentage of Subjects Hospitalized Due to COVID-19 or Died Due to Any Cause
Time frame: Day 1 through Day 29
Percentage of Subjects Who Died Due to Any Cause
Time frame: Day 1 through Day 29; Day 1 through Day 60
Percentage of Subjects With COVID-19-related Complications
Time frame: Day 1 through Day 29
Percentage of Subjects With COVID-19-medically Attended Visits (Hospitalization, Emergency Room (ER) Visit, Urgent Care Visit, Physician's Office Visit, or Telemedicine Visit) or Who Died Due to Any Cause
Time frame: Day 1 through Day 29; Day 1 through Day 60
Percentage of Subjects With COVID-19 Symptom Relapse
Time frame: Day 1 through Day 29
Percentage of Subjects With Viral Load Rebound
Time frame: Day 1 through Day 29
| Milestone | BEM - SCO Stratum | PBO - SCO Stratum | BEM - Combo Stratum | PBO - Combo Stratum |
|---|---|---|---|---|
| Started | 1104 | 1107 | 38 | 36 |
| Completed | 1073 | 1087 | 37 | 35 |
| Not completed | 31 | 20 | 1 | 1 |
| Milestone | BEM - SCO Stratum | PBO - SCO Stratum | BEM - Combo Stratum | PBO - Combo Stratum |
|---|---|---|---|---|
| Started | 1073 | 1087 | 37 | 35 |
| Completed | 1071 | 1083 | 37 | 35 |
| Not completed | 2 | 4 | 0 | 0 |
| Participants | BEM - SCO Stratum | PBO - SCO Stratum | BEM - Combo Stratum | PBO - Combo Stratum |
|---|---|---|---|---|
| Percentage of Subjects Hospitalized for Any Cause or Died Due to Any Cause | 7 | 2 | 0 | 0 |
| Participants | BEM - SCO Stratum | PBO - SCO Stratum | BEM - Combo Stratum | PBO - Combo Stratum |
|---|---|---|---|---|
| Percentage of Subjects Hospitalized Due to COVID-19 or Died Due to Any Cause | 4 | 2 | 0 | 0 |
| Participants | BEM - SCO Stratum | PBO - SCO Stratum | BEM - Combo Stratum | PBO - Combo Stratum |
|---|---|---|---|---|
| Through Day 29 | 2 | 1 | 0 | 0 |
| Through Day 60 | 3 | 1 | 0 | 0 |
| Participants | BEM - SCO Stratum | PBO - SCO Stratum | BEM - Combo Stratum | PBO - Combo Stratum |
|---|---|---|---|---|
| Percentage of Subjects With COVID-19-related Complications | 3 | 4 | 0 | 0 |
| Participants | BEM - SCO Stratum | PBO - SCO Stratum | BEM - Combo Stratum | PBO - Combo Stratum |
|---|---|---|---|---|
| Through Day 29 | 7 | 11 | 1 | 0 |
| Through Day 60 | 8 | 12 | 1 | 0 |
| Participants | BEM - SCO Stratum | PBO - SCO Stratum | BEM - Combo Stratum | PBO - Combo Stratum |
|---|---|---|---|---|
| Percentage of Subjects With COVID-19 Symptom Relapse | 272 | 265 | 13 | 12 |
| Participants | BEM - SCO Stratum | PBO - SCO Stratum | BEM - Combo Stratum | PBO - Combo Stratum |
|---|---|---|---|---|
| Percentage of Subjects With Viral Load Rebound | 79 | 102 | 4 | 5 |
Collected over Through Day 60. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BEM - SCO Stratum | 3/1,093 (0.3%) | 9/1,093 (0.8%) | 39/1,093 (3.6%) |
| PBO - SCO Stratum | 1/1,103 (0.1%) | 2/1,103 (0.2%) | 35/1,103 (3.2%) |
| BEM - Combo Stratum | 0/37 (0%) | 0/37 (0%) | 6/37 (16.2%) |
| PBO - Combo Stratum | 0/36 (0%) | 0/36 (0%) | 9/36 (25%) |
| Event | BEM - SCO Stratum | PBO - SCO Stratum | BEM - Combo Stratum | PBO - Combo Stratum |
|---|---|---|---|---|
| BradyarrhythmiaCardiac disorders | 1/1093 | 0/1103 | 0/37 | 0/36 |
| Cardiac failureCardiac disorders | 1/1093 | 0/1103 | 0/37 | 0/36 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/1093 | 0/1103 | 0/37 | 0/36 |
| VomitingGastrointestinal disorders | 1/1093 | 0/1103 | 0/37 | 0/36 |
| COVID-19Infections and infestations | 1/1093 | 1/1103 | 0/37 | 0/36 |
| Anaesthetic complicationInjury, poisoning and procedural complications | 1/1093 | 0/1103 | 0/37 | 0/36 |
| HyponatraemiaMetabolism and nutrition disorders | 1/1093 | 0/1103 | 0/37 | 0/36 |
| HypernatraemiaMetabolism and nutrition disorders | 1/1093 | 0/1103 | 0/37 | 0/36 |
| Transient ischaemic attackNervous system disorders | 1/1093 | 0/1103 | 0/37 | 0/36 |
| Renal impairmentRenal and urinary disorders | 1/1093 | 0/1103 | 0/37 | 0/36 |
| Event | BEM - SCO Stratum | PBO - SCO Stratum | BEM - Combo Stratum | PBO - Combo Stratum |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 24/1093 | 24/1103 | 4/37 | 3/36 |
| DysguesiaNervous system disorders | 0/1093 | 0/1103 | 3/37 | 1/36 |
| NauseaGastrointestinal disorders | 11/1093 | 10/1103 | 1/37 | 2/36 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 3/1093 | 4/1103 | 0/37 | 2/36 |
| HyponatraemiaMetabolism and nutrition disorders | 2/1093 | 2/1103 | 0/37 | 2/36 |
Modified intent-to-treat (mITT) population included subjects who received \>= 1 dose of study drug and had \>= 1 positive SARS-CoV-2 result through Day 5.
| Age, Customized(Participants) | BEM - SCO Stratum | PBO - SCO Stratum | BEM - Combo Stratum | PBO - Combo Stratum | Total |
|---|---|---|---|---|---|
| 18-49 years | 28 | 30 | 1 | 2 | 61 |
| 50-64 years | 429 | 432 | 13 | 13 | 887 |
| 65-79 years | 486 | 487 | 18 | 17 | 1008 |
| >= 80 years | 79 | 84 | 4 | 2 | 169 |
| Sex: Female, Male(Participants) | BEM - SCO Stratum | PBO - SCO Stratum | BEM - Combo Stratum | PBO - Combo Stratum | Total |
|---|---|---|---|---|---|
| Female | 613 | 634 | 18 | 22 | 1287 |
| Male | 409 | 399 | 18 | 12 | 838 |
| Ethnicity (NIH/OMB)(Participants) | BEM - SCO Stratum | PBO - SCO Stratum | BEM - Combo Stratum | PBO - Combo Stratum | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 861 | 875 | 16 | 18 | 1770 |
| Not Hispanic or Latino | 123 | 131 | 19 | 16 | 289 |
| Unknown or Not Reported | 38 | 27 | 1 | 0 | 66 |
| Race (NIH/OMB)(Participants) | BEM - SCO Stratum | PBO - SCO Stratum | BEM - Combo Stratum | PBO - Combo Stratum | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 8 | 11 | 1 | 0 | 20 |
| Asian | 68 | 55 | 3 | 1 | 127 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 73 | 73 | 3 | 2 | 151 |
| White | 867 | 882 | 24 | 28 | 1801 |
| More than one race | 1 | 4 | 0 | 0 | 5 |
| Unknown or Not Reported | 5 | 8 | 5 | 3 | 21 |
Showing the first 100 of 264 sites across 19 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2022 to primary completion in Apr 2024, 17 months.
Results were first posted in Jun 2025, 1 year 1 month after primary completion.
Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 17 months is above that.
Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bemnifosbuvir